NCT00706004

Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University of Arkansas · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the short term safety and effectiveness of lubiprostone when used for constipation in adults with cystic fibrosis.

Detailed description

Cystic fibrosis (CF) affects about 30,000 people in the United States. It is caused by an absent or dysfunctional protein called CF transmembrane conductance regulator (CFTR) which functions as a chloride channel. Lubiprostone is a medication indicated for constipation that activates type 2 chloride channels (ClC-2) and has the potential to be an effective treatment for constipation in adults with CF. It has the potential to correct the underlying disorder by utilizing a chloride channel whose activity does not depend on CFTR. This project is a prospective open-label pilot study to examine the safety and effectiveness of lubiprostone when used in adults with CF with constipation. The specific aims are as follows: 1) Determine the effectiveness of lubiprostone for constipation in participants with CF, and 2) Determine the short term safety of lubiprostone in adults with CF. Data will also be collected to generate further information about the effect of lubiprostone on nutritional status.

Conditions

• Constipation
• Cystic Fibrosis

Interventions

Type	Name	Description
DRUG	lubiprostone	lubiprostone 24 microgram capsule taken twice daily for 4 weeks

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2008-06-27
• Last updated: 2011-04-18
• Results posted: 2011-04-18

Locations

1 site across 1 country: United States